GMP News, GMP guidelines, GMP Violations, GMP warnings A Public Health Global News Portal

Welcome to gmpviolations.com FDA, WHO, EU, TGA, CDSCO guidelines...and GMP Violations news/warning letters..

150000+ Industry Leaders already read it everyday

Wednesday, March 21, 2018

FDA has issued form 483 to Dr. Reddy's Laboratory | API | IDA Bollaram | GMP VIOLATIONS |


FDA has insured form 483  to Dr. Reddy's Laboratory | API | IDA Bollaram | GMP VIOLATIONS |








The US FDA has been inspected the Dr. Reddy's laboratory located at IDA Bollaram which is manufacturing of Active pharmaceutical ingredients. The form 483 has been issued with 5 observations.


OBSERVATION 1:
The responsibilities and procedures applicable to the Quality control unit are not fully followed. Specially 

      A)     Your quality unit failure to close multiple CAPAs within allowable timeframe and justification to extend the completion timeframe was not requested. Specifically, your quality unit did not request an extension to the few CAPAs.

      B)      One of QC laboratory Audit trail reviewed and found discrepancy which is having without logging incident. And proper justification found.

      C)      Failed to establish Quality agreements with starting materials suppliers

      D)     Failure to follow the Incident reporting system as per your site SOP.

OBSERVATION 2:
Procedures describing the handling of written and oral complaints related to API Materials are not followed.

     A)     In adequate closure of market complaint closure without tracking fulfillment.
     B)     Complaint investigation concluded with CAPA, no CAPA has logged and not implemented the            SOP revision.

OBSERVATION 3:
Building used in the manufacturing, processing, packing of API finished materials are not maintained in a good state of repair.
As the facility containment not meeting as required.

OBSERVATION 4:
Separate or defined areas to prevent contamination or mix-ups are deficient regarding operations related to the quarantine storage of API finished materials prior to release.

OBSERVATION 5:
There is NO assurance that the equipment used in the production of ___ and ___API are always maintained and kept in under proper conditions for manufacturing operations and no prevent the contamination of the products.

A)     Failure to fulfil the record sheets as required
B)      A piece of fabric thread was  observes the inside the filled container

C)      Presence of product was observed inside the following production equipment.


www.gmpviolations.com GMP News, GMP guidelines, GMP Violations, GMP warnings, GMP Trends. A Public Health Global News Portal. (This story has not been edited by GMP Violations staff and is auto-generated from a syndicated feed/ experts experiences sharing.) Disclaimer: The Logos/Images & content posted here are belongs to respective to Authority / owners of firm. The Article posted under public health importance news. Please ensure the guideline as per Regulatory agencies.
Share:

0 comments:

Post a Comment

Related Posts Plugin for WordPress, Blogger...

AMAZON BEST DEALS

Popular Posts

AMAZON BEST DEALS

Subscribe Free GMP Guidelines

Enter your email address:

Delivered by FeedBurner

Followers

Printfriendly

Subscribe via email for free

Services

Enter your email address:

Delivered by FeedBurner

Contact Form

Name

Email *

Message *

Menu :
Powered by Blogger.

Visitors

    Translater

    Related Posts Plugin for WordPress, Blogger...

    Category

    2016 (37) 2017 (85) 2018 (9) 211 CFR (1) 211.63 (1) 483 (5) AAFA (1) Abbott (2) AboutUs (1) ALCOA (1) Alerts (2) ANDA (1) Anshu (2) Antibiotics (1) apic (1) APR17 (8) APS (2) Articles (4) AstraZeneca (1) Aug17 (2) Aurobindo (2) Author (2) Authors (8) Biocon (1) cadila (1) capa (3) CDSCO (5) Change control (1) Christian Green (1) cipla (2) Cleaning validation (1) Data Integrity (9) dec16 (15) Definations (1) Deviations (1) Donald Trump’s (2) Downloads (17) Dr.Reddy's (4) eca (1) EIR (1) Eli Lilly (1) ema (12) EU (9) FDA (70) FDA Guide (18) FEB17 (15) Genaral (1) General Health (2) GMP (1) GMP News (36) gsk (2) GuidelineEU (10) GuidelinesG (5) GuidelineW (2) GV/0117/001 (1) GVAuthors (3) Health (4) HOSPIRA (1) ICH (3) ICHGuide (3) import alert (1) India (1) ISPE (1) James Bullock (1) JAN17 (23) Jul17 (8) July17 (1) Jun17 (4) Lupin (2) Mahender (39) MAR17 (13) Mar18 (7) May17 (10) MHRA (3) MHRA guide (1) Mumbai (1) Mylan (4) Natco (1) News (55) Non Complinaces (1) Nov16 (5) Novartis (1) oct (1) Oct16 (10) OCT17 (1) PDA (1) Personnel (1) pfizer (1) pics (8) Picsguide (2) QbD (1) Quality Docs (1) RCA (1) Recall (1) safety (1) Sanjeev Kumar Singh (4) Sanofi (1) Sep16 (6) Siegfried Schmitt (2) SUN (1) TGA (3) TOP 10 PHARMA (1) USP (2) Validation (3) Warning Letters (43) WHO (6) zika (1)

    Sponsors

    Theme Support